• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Enabling Statisticians to Lead through Innovation and Excellence

    Enabling Statisticians to Lead through Innovation and Excellence

Search The Effective Statistician

  • Winning with Words and Graphs: The Effective Statistician presentation and data visualization masterclass
  • How to be an effective statistician
  • Start here!
  • Podcast
    • PSI Careers
  • Free resources on visualization
    • Recording available: Flatten the curve – learnings from COVID-19 visualizations to better explore and communicate your data
  • Free resources on influencing
    • The Effective Statistician Leadership Program
    • Recording available: It’s not enough to be right!
  • Join The Effective Statistician LinkedIn group
  • Quick tips to be more effective
  • Legal disclosure – about us
    • Datenschutzerklärung – sorry, still in German…
You are here: Home / Innovation / 50 shades of pre-specification

50 shades of pre-specification

By Alexander on 2019-05-07 0

50 shades of pre-specification
  • share 
  • tweet  
  • share  
  • share 
  • save  

Interview with Lovisa Berggren

Prespecified=good and post-hoc=bad. This is how we as statistician see it usually and I did too. However, over the past years I realized more and more, that it’s not that easy.

How many details do you need to have to call an analysis pre-specified? Should we label a request to analyse a certain subgroup by regulators as well as a fishing expedition to find a significant subgroup both in the same way: post-hoc?

Lovisa and I together with some others are presenting at the next PSI conference about this topic and today, we dive into this topic and identify different dimension to be considered to understand better the different shades pre-specified analyses.

Listen to this episode to avoid oversimplification and confusion in discussions in the future.

About Lovisa Berggren

Lovisa Berggren (MSc), Senior statistical consultant, Freelancing consultant specialized in HTA submissions, data mining and analyses of integrated clinical trials data. With a focus on Phase III and IV neuroscience, autoimmune and oncology.

Lovisa gained her initial experienced as a statistician working 3.5 years with AstraZeneca. During this time she prepared and attended two public oral advisory committee meetings with the FDA and one EMA oral hearing for new indications with Quetiapine (neuroscience). Her job also including leading and coordinating big teams of statisticians and programmers under high pressure. A

After AstraZeneca Lovisa joined ImClone for 1.5 years as a contractor working on two phase III trials in oncology. During the restructuring and merger of ImClone and Eli Lilly Lovisa moved over to work as a contractor for Eli Lilly. During her 5.5 years with Lilly she has worked with a number of datamining projects and publications (autoimmune and neuroscience). As well as in the role of lead statistician for the HTA submission of ixekizumab. Lovisa is currently working part time for Eli Lilly and Cogitars.

In parallel, she conducting her PhD at the UMIT University in Austria. Her PhD thesis focuses on methods for evaluating consistency of treatment effects in HTA reimbursement submissions.

Never miss an episode of The Effective Statistician

Join hundreds of your peers and subscribe to get our latest updates by email!

Get the shownotes of our podcast episodes plus tips and tricks to increase your impact at work to boost your career!

Success! Now check your email to confirm your subscription.

There was an error submitting your subscription. Please try again.

We won't send you spam. Unsubscribe at any time. Powered by ConvertKit
  • share 
  • tweet  
  • share  
  • share 
  • save  

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Join the PSI newsletter here!

Categories

  • Excellence
  • Innovation
  • Knowledge
  • Leadership
  • PSI Calc Podcast

Recent Posts

  • Extrapolation to paedriatics
  • How to integrate external data into your clinical studies: from theory to application
  • A preview into the PSI conference
  • Patient-reported outcomes and the FDA Patient-Focused Drug Development Guidance
  • Apps on prescription paid by the government

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018

The podcast is run in association with PSI

Copyright © 2022 · Smart Passive Income Pro on Genesis Framework · WordPress · Log in